Hanyu Pharmaceutical: HY3003 Injection Receives Approval Notice for Drug Clinical Trials
2026-11-19 17:05:29
According to CoinMeta, Hanyu Pharmaceutical announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration regarding the HY3003 injection, approving the conduct of clinical trials for this product in the indication of human weight management. HY3003 is a new type of GLP-1R / GIPR / GCGR triple receptor agonist that the company has been developing. The approved injection is administered via subcutaneous injection once a week. Currently, the global research and development of this project is progressing smoothly. The HY3003 injection has already obtained clinical trial authorization from the US FDA and is advancing overseas clinical development. The company has also submitted an application for a drug clinical trial for the HY3003 tablet to the National Medical Products Administration, which has been accepted.
Source:Jin10 Data
This content is for market information only and does not constitute investment advice.
Follow WalletJYS official accounts to stay updated

Hot Articles
Refresh

What Is Bitmine? Why the Largest ETH Treasury Halted Buys
11-17 11:29

NVIDIA's stock tumbles 9% after the latest announcement; what impact will NVIDIA's decline have on the AI industry?
11-12 16:08

Is the Tangem wallet secure? No need to memorize a mnemonic phrase, can beginners use it with confidence?
11-12 17:31

SOL Currency's Latest Price Outlook: Can It Break Through the $90 Barrier?
11-11 11:59

Dow Jones 1,000-Point Swings: CPI Reversal or Bull Trap?
11-10 16:56



